Navigation Links
QLT announces positive Health Canada decision on Aczone(R)

Blood testing requirements removed

VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that Health Canada has completed its review of QLT USA, Inc.'s labeling supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate dehydrogenase (G6PD) screening and blood monitoring requirements.

"We are extremely pleased to report Health Canada's decision to remove the need for blood monitoring from the Aczone label," said Bob Butchofsky, President and Chief Executive Officer of QLT. "This positive review, along with the FDA's recent decision to also remove the need for blood monitoring from the Aczone label, validates our regulatory strategy, increases Aczone's commercial potential, and enhances the product's overall attractiveness to potential acquirers."

Aczone was originally approved by Health Canada in June 2006 with a similar label restriction as that required by the US Food and Drug Administration (FDA). The label called for all patients to undergo G6PD screening and for those patients with this enzyme deficiency, regular blood monitoring was required during Aczone treatment. On March 17, 2008 the Company announced that the FDA removed the G6PD screening and monitoring requirements based on a Phase IV clinical trial in 56 safety-evaluable G6PD-deficient patients. During a six-month period, patients were treated with both Aczone and the Aczone-vehicle (control group) in a cross-over design. Data was analyzed by third party clinical experts in dermatology and hematology who concluded that no clinically meaningful changes in safety-related parameters were observed in the trial.

Aczone, a prescription topical medicine for the treatment of acne vulgaris, is the only acne treatment to harness the potential of dapsone in a topical formulation to provide patients with a convenient and effective therapy. QLT USA owns worldwide marketing rights to Aczone.

About Aczone(R)

ACZONE is an aqueous topical gel containing 5% dapsone. Combining dapsone in QLT USA's proprietary Solvent Microparticulate (SMP(TM)) gel enables dapsone to be applied topically and safely. In two randomized double-blind, vehicle-controlled clinical studies in 3,000 acne patients, ACZONE Gel achieved statistically significant percent reduction in the number of acne lesions and better success rate on the Global Acne Assessment Score. The most common adverse events reported from controlled clinical trials include oiliness/peeling, dryness, and erythema. There were no significant differences in the adverse event rates between ACZONE Gel and vehicle control treated patients.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne and Eligard(R) and future product opportunities. For more information, visit our web site at

Aczone is a registered trademark of QLT USA, Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on the NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

CONTACT: QLT Inc.: Vancouver, Canada: Therese Hayes, Telephone: (604) 707-7000, or 1-800-663-5486, Fax: (604) 707-7001; The Trout Group: New York, USA: Brandon Lewis, Telephone: (646) 378-2915; or Marcy Strickler, Telephone: (646) 378-2927

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
2. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
3. Biopure Announces MHRA Meeting Update
4. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
5. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
6. American Oriental Bioengineering Announces that it Withdraws Convertible Preferred Stock Offering
7. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
8. Synthetech Announces Fiscal 2008 Results
9. Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance
10. Martek Announces Second Quarter 2008 Financial Results
11. WWMR, Inc. Announces Launch of New Pain Clinic Monitor
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
(Date:10/27/2015)... 2015 In the present market scenario, security ... various industry verticals such as banking, healthcare, defense, electronic ... demand for secure & simplified access control and growing ... hacking of bank accounts, misuse of users, , and ... PC,s, laptops, and smartphones are expected to provide potential ...
(Date:10/26/2015)... Oct. 26, 2015  Delta ID Inc., a company ... mobile and PC devices, announced its ActiveIRIS® technology powers ... NX F-02H launched by NTT DOCOMO, INC in ... the second smartphone to include iris recognition technology, after ... NX F-04G in May 2015, world,s first smartphone to ...
Breaking Biology News(10 mins):